A new study suggests that a ‘Sit Less’ intervention ‒ breaking sitting with standing and light-intensity walking ‒ may be an alternative to structured exercise to promote blood sugar control in patients with type 2 diabetes, giving improved 24-hour glucose levels and improved insulin sensitivity.
Adding evolocumab to optimised statin therapy results in statistically significant regression of atherosclerosis in patients with coronary artery disease, according to results from the GLAGOV phase 3 trial.
Tackling obesity by offering the opportunity to attend a weight loss programme during a routine consultation is effective, welcomed by patients and takes only 30 seconds, according to a new randomised trial of over 1800 people in the UK.
The UK charity Heart Valve Voice has developed the first practical guidance in heart valve disease for primary care. The disease is under-diagnosed and yet is increasing in prevalence as the population ages, so there is a need for primary care to plan an appropriate response.
Sacubitril/valsartan (Entresto), the first angiotensin receptor-neprilysin inhibitor (ARNI), is a recently licensed medication that has been shown to improve outcomes for patients with symptomatic chronic HF with reduced ejection fraction (HF-REF) compared with current gold-standard treatment with an ACE inhibitor. This article describes the pharmacist’s role in supporting patients receiving sacubitril/valsartan.
Commissioning is not so different from seeing patients. As a GP you listen, examine, draw up a diagnosis and plan treatment. In commissioning, the community served by the clinical commissioning group (CCG) is the ‘patient’. When considering the introduction of a new treatment for heart failure (HF) such as sacubitril/valsartan (Entresto), we must consider not only its acquisition costs but also its potential benefits in improving patients' symptoms and reducing expensive hospital admissions.
Many patients with heart failure rely on practice nurses to monitor their care. A multidisciplinary team (MDT) integrated community approach has been endorsed by NICE guidelines when delivering HF care. This article provides practice nurses with the information they need to understand the condition, current treatment guidelines, and the new treatment – sacubitril/valsartan, the first-in-class angiotensin receptor-neprilysin inhibitor.